Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | STS | P08842 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 1/20 | 0.68 |
| ▸ | CA12 | O43570 | 12/20 | 0.60 |
| ▸ | CA9 | Q16790 | 12/20 | 0.60 |
| ▸ | CA1 | P00915 | 10/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | CA6 | P23280 | 4/20 | 0.60 |
| ▸ | CA7 | P43166 | 4/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.60 |
| ▸ | CA4 | P22748 | 4/20 | 0.60 |
| ▸ | CA5A | P35218 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.60 |
| ▸ | CA3 | P07451 | 2/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 7-Methanesulfonyloxycoumarin SCHEMBL10851014 | 0.83 | GAA (0.71) | GLAGAASTSMAOBCA12 | |
| SCHEMBL17318081 | 0.83 | GLA (0.71) | GLAGAASTSMAOBCA12 | |
| Potassium Ion SCHEMBL29669597 | 0.82 | GLA (0.69) | GLAGAASTSMAOBCA12 | |
| SCHEMBL10849811 | 0.81 | MAOB (1.00) | GLAGAASTSMAOBCA12 | |
| SCHEMBL9432106 | 0.81 | GLA (0.68) | GLAGAASTSMAOBCA12 | |
| SCHEMBL4419653 | 0.81 | GLA (0.68) | GLAGAASTSMAOBCA12 | |
| Hydrogen Sulfide SCHEMBL6878856 | 0.80 | GLA (0.66) | GLAGAASTSMAOBCA12 | |
| SCHEMBL10848120 | 0.80 | GLA (0.66) | GLAGAASTSMAOBCA12 | |
| SCHEMBL18284636 | 0.79 | CA12 (0.68) | GLAGAASTSMAOBCA12 | |
| SCHEMBL6911982 | 0.78 | GAA (0.64) | GLAGAASTSMAOBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911737-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | Optimvia, LLC (US) | 2021-11-24 | — | — | EP | claimed |
| CN-113646427-A | Engineered arylsulfate-dependent enzymes | 奥普蒂姆维亚有限公司 | 2021-11-12 | — | — | CN | claimed |
| WO-2020150350-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | OPTIMVIA, LLC (US) | 2020-07-23 | — | — | WO | claimed |
| EP-1891208-B1 | NOVEL CELLULAR COMPOSITIONS AND METHODS FOR THEIR PREPARATION | CELSIS IN VITRO INC (US) | 2012-06-06 | — | — | EP | claimed |
| EP-4707382-A1 | METHOD FOR PRODUCING METABOLICALLY ACTIVATED LIVER ORGANOID, COMPOSITION, AND METHOD FOR EVALUATING TEST SUBSTANCE | JSR Corporation (JP) | 2026-03-11 | — | — | EP | disclosed |
| EP-3846938-B1 | IMMOBILIZED ENZYMES AND MICROSOMES ON MAGNETIC SCAFFOLDS | ZYMTRONIX CATALYTIC SYSTEMS INC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20240093166-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | GINKGO BIOWORKS, INC. | 2024-03-21 | — | — | US | disclosed |
| US-20240076634-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | GINKGO BIOWORKS, INC. | 2024-03-07 | — | — | US | disclosed |
| US-20240002819-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | GINKGO BIOWORKS, INC. | 2024-01-04 | — | — | US | disclosed |
| EP-2479259-B1 | Multi-cryopreserved hepatocytes and methods for their preparation | IN VITRO INC (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-117062605-A | Methods of treating diseases using treprostinil prodrugs | 联合治疗公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230340552-A1 | METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES | GINKGO BIOWORKS, INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2006052223-A1 | CELL CULTURE DEVICE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2006-05-18 | — | — | WO | disclosed |
| US-20050239042-A1 | Novel cellular compositions and methods for their preparation | IN VITRO TECHNOLOGIES, INC. (US) | 2005-10-27 | — | — | US | disclosed |
| US-20040161479-A1 | Inhibition of CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes by a Tripterygium Wilfordii Hook. F. extract | NOVEMED GROUP LIMITED | 2004-08-19 | — | — | US | disclosed |
| US-20040047920-A1 | Inhibition of CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes by a Tripterygium Wilfordii Hook.F. extract | NOVEMED GROUP LIMITED | 2004-03-11 | — | — | US | disclosed |
| US-20040029153-A1 | Method for estimating metabolic function of xenobiotic and induction thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-12 | — | — | US | disclosed |
| WO-2003105663-A2 | LIVER ASSIST SYSTEM BASED ON HOLLOW FIBER CARTRIDGES OR ROTATING BIOREACTOR | STELSYS LLC (US) | 2003-12-24 | — | — | WO | disclosed |
| EP-1356286-A2 | METHOD FOR ESTIMATING METABOLIC FUNCTION OF XENOBIOTIC AND INDUCTION THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002040995-A2 | METHOD FOR ESTIMATING METABOLIC FUNCTION OF XENOBIOTIC AND INDUCTION THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340552-A1 | METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES | CSGALNACT1, NANS, STS | GLA 329/4885GAA 882/4885STS 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.